Dermata Therapeutics, INC 10-Q quarterly reports

Dermata Therapeutics reports a net loss of $2.97 million for Q2 2026, faces going concern uncertainty, and is engaged in significant litigation with a former licensor, while preparing for its Tome skincare product launch.

Dermata Therapeutics reports Q1 2026 results, detailing a strategic pivot to direct-to-consumer skincare and ongoing legal challenges.

Dermata Therapeutics, Inc. announced a strategic shift to over-the-counter dermatology products following positive Phase 3 trial results for XYNGARI, while reporting continued net losses and a going concern warning.

Dermata Therapeutics, a clinical-stage dermatology company, reported a reduced net loss in Q2 2025 and positive Phase 3 trial results for its lead acne candidate XYNGARI, but faces significant going concern doubts and Nasdaq delisting risk.

Dermata Therapeutics reports positive topline results from its Phase 3 STAR-1 clinical trial for XYNGARI and provides a financial update for the quarter ended March 31, 2025.

Dermata Therapeutics reports a net loss of $3.2 million for the third quarter of 2024, with increased research and development expenses due to ongoing Phase 3 clinical trials.

Dermata Therapeutics reports a net loss of $2.8 million for the second quarter of 2024, with ongoing clinical trial expenses impacting financials.

Dermata Therapeutics reported a net loss of $3.1 million for the first quarter of 2024, with ongoing clinical trial expenses impacting financials.